financetom
Business
financetom
/
Business
/
Acadia Healthcare's Revised Long-Term Growth Targets 'Reasonable,' RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Acadia Healthcare's Revised Long-Term Growth Targets 'Reasonable,' RBC Says
May 28, 2025 8:16 AM

10:50 AM EDT, 05/28/2025 (MT Newswires) -- Acadia Healthcare's ( ACHC ) revised long-term growth targets are "reasonable" as they reflect the longer ramp of new facilities, RBC Capital Markets said in a Tuesday note.

The company provided additional commentary on its revised long-term outlook, saying that the lower-than-expected earnings before interest, taxes, depreciation, and amortization was mainly related to the longer ramp of new facilities compared to expansion beds, RBC analysts noted.

Acadia management also pointed out conservatism related to rate growth assumptions, given uncertainty surrounding policy and the macro environment, the analysts said.

The analysts said the company's clarifications "comprise a reasonable basis" for the revised long-term outlook.

RBC maintained its outperform rating and $43 price target on the stock.

Price: 23.04, Change: -0.48, Percent Change: -2.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cassava Sciences Licenses Simufilam Patent From Yale University for Potential Treatment of Seizures; Shares Rise
Cassava Sciences Licenses Simufilam Patent From Yale University for Potential Treatment of Seizures; Shares Rise
Feb 27, 2025
11:14 AM EST, 02/27/2025 (MT Newswires) -- Cassava Sciences ( SAVA ) said Thursday it has entered into a license agreement with Yale University for intellectual property rights, including an exclusive US method of treatment patent covering simufilam as a potential treatment for seizures linked to rare neurodevelopmental disorders such as tuberous sclerosis complex. The licensed patent is based on...
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million
Feb 27, 2025
11:11 AM EST, 02/27/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Thursday it has signed a deal to sell its rare pediatric disease priority review voucher for $150 million, with transaction expected within 30 to 45 days. Zevra was granted the voucher in September last year following Miplyffa approval by the US Food and Drug Administration. Shares of...
US CFPB drops enforcement action against Capital One
US CFPB drops enforcement action against Capital One
Feb 27, 2025
(Reuters) - The U.S. Consumer Financial Protection Bureau on Thursday dropped a legal action against Capital One, which the agency had accused last month of cheating consumers out of more than $2 billion in interest payments on savings accounts. The dismissal continues President Donald Trump's rapid moves to dismantle the agency, which he has said should be eliminated, but came...
Bath & Body Works Fourth-Quarter Sales Decline; 2025 Earnings Outlook Disappoints
Bath & Body Works Fourth-Quarter Sales Decline; 2025 Earnings Outlook Disappoints
Feb 27, 2025
11:14 AM EST, 02/27/2025 (MT Newswires) -- Bath & Body Works ( BBWI ) on Thursday reported a year-year-year drop in fiscal fourth-quarter sales, while the retailer offering body care products and home fragrances set expectations for a likely earnings decline this year. Revenue fell to $2.79 billion for the three months ended Feb. 1 from $2.91 billion the year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved